What is Danaher's biotechnology — identifiable assets?

Danaher (DHR) reported biotechnology — identifiable assets of $36.01B in Q2 2026.

How has Danaher's biotechnology — identifiable assets changed year-over-year?

Danaher's biotechnology — identifiable assets decreased by 4.1% year-over-year, from $37.56B to $36.01B.

What does biotechnology — identifiable assets mean?

The total value of assets that can be directly attributed to the biotechnology segment, including inventory, property, plant, equipment, and intangible assets. This metric is used to evaluate the capital intensity and asset utilization of the segment. It helps investors understand the asset base required to generate the segment's revenue.

Danaher DHR Biotechnology — Identifiable assets

Other segment segments

Diagnostics

$25.73B+77.0%

Life Sciences

$22.59B-3.4%

Similar metrics at other companies

CNT

CNTNClinical Stage Bio Technology — Total Assets

$1.66M—

VAN

VANIBiopharm Division — Total Assets

$41.9M+20.7%

ASHLife Sciences — Total Assets

$1.46B-22.4%

DUOTTechnologies — Total Assets

$2.77M-76.1%

PKOHSupply Technologies Segment — Identifiable assets

$501M+2.4%

ACNTIdentifiable assets

$27.98M+31.3%

Other financials

Income statement

See full

Revenue$6.3B+5.5%

Gross profit$3.6B+2.5%

Operating income$1.1B+48.3%

Net income$870.0M+56.8%

EPS (diluted)$1.23+59.7%

Balance sheet

See full

Cash & equivalents$4.3B+47.0%

Total debt$27.9B+50.1%

Total equity$52.6B+0.5%

Total assets$92.4B+13.2%

Cash flow

See full

Operating cash flow$1.5B+14.6%

CapEx$269.0M+8.5%

Free cash flow$1.3B+16.1%

Valuation

See full

Market cap$134.62B-7.4%

Enterprise value$158.13B-1.7%

P/E33.6×-9.0×

P/S5.4×-0.7×

Profitability

See full

Gross margin58.5%-1.1pp

Operating margin20.4%+2.0pp

Net margin15.9%+1.7pp

FCF margin21.8%+1.5pp

Returns & leverage

See full

Return on equity7.6%+1.0pp

Debt / equity0.5×+0.2×

Current ratio1.7×0.0×

Where this comes from

Reported directly by Danaher in its filing.

Tagged under the XBRL concept us-gaap:Assets.

The official record: Danaher’s 10-Q, filed July 21, 2026, on SEC EDGAR. View the filing →

Ask your AI about Danaher's biotechnology — identifiable assets.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Danaher's biotechnology — identifiable assets?: Danaher (DHR) reported biotechnology — identifiable assets of $36.01B in Q2 2026.
How has Danaher's biotechnology — identifiable assets changed year-over-year?: Danaher's biotechnology — identifiable assets decreased by 4.1% year-over-year, from $37.56B to $36.01B.
What does biotechnology — identifiable assets mean?: The total value of assets that can be directly attributed to the biotechnology segment, including inventory, property, plant, equipment, and intangible assets. This metric is used to evaluate the capital intensity and asset utilization of the segment. It helps investors understand the asset base required to generate the segment's revenue.